


IRE1

Inositol requiring enzyme 1

HDAC Inhibitor:
Vorinostat (SAHA)













HDAC (Histone deacetylase)

The serine/threonine-protein kinase/endoribonuclease inositol-requiring enzyme 1 (IRE1) is an enzyme that in humans is encoded by the ERN1 gene. IRE1 is an endoplasmic reticulum (ER) transmembrane sensor that activates UPR to maintain ER and cellular function. While mammalian IRE1 promotes cell survive, it can initiate apoptosis via decay of anti-apoptotic microRNAs.

IRE1 activation is initiated by homotypic interactions of the stress-sensing luminal domain favoring transautophosphorylation of the kinase-extension nuclease (KEN) domain on the cytoplasmic side of the ER membrane.

IRE1/XBP-1 has been shown to regulate a variety of genes in various cell types in response to ER stress, mostly related to ER function and the secretory pathway, although the target genes vary depending on the cell type and nature of the stress stimuli.

IRE1 Inhibitors & Modulators

<p>3,6-DMAD hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-U00460</p> <p>Bioactivity: 3,6-DMAD hydrochloride is a inhibitor of the IRE1α-XBP1 pathway of the unfolded protein response.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg</p> 	<p>4μ8C (IRE1 Inhibitor III)</p> <p style="text-align: right;">Cat. No.: HY-19707</p> <p>Bioactivity: 4μ8C (IRE1 Inhibitor III) is a small-molecule inhibitor of IRE1α.</p> <p>Purity: 98.52%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>6-Bromo-2-hydroxy-3-methoxybenzaldehyde (NSC95682)</p> <p style="text-align: right;">Cat. No.: HY-107371</p> <p>Bioactivity: 6-Bromo-2-hydroxy-3-methoxybenzaldehyde (NSC95682) is an IRE-1α inhibitor with an IC₅₀ of 0.08 μM, extracted from patent WO 2008154484 A1, IRE-1α inhibitor compound 3-5.</p> <p>Purity: 99.87%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 50 mg</p> 	<p>APY29</p> <p style="text-align: right;">Cat. No.: HY-17537</p> <p>Bioactivity: APY29 is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation with IC₅₀ of 280 nM and activates IRE1α RNase activity.</p> <p>Purity: 99.54%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 
<p>B I09</p> <p style="text-align: right;">Cat. No.: HY-107400</p> <p>Bioactivity: B I09 is an IRE-1 RNase inhibitor, with an IC₅₀ of 1230 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 500 mg, 250 mg</p> 	<p>GSK2850163</p> <p style="text-align: right;">Cat. No.: HY-U00459</p> <p>Bioactivity: GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC₅₀s of 20 and 200 nM, respectively.</p> <p>Purity: 98.50%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</p> 
<p>GSK2850163 hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-U00459B</p> <p>Bioactivity: GSK2850163 hydrochloride is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC₅₀s of 20 and 200 nM, respectively.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p> 	<p>KIRA6</p> <p style="text-align: right;">Cat. No.: HY-19708</p> <p>Bioactivity: KIRA6 allosterically inhibits IRE1α RNase kinase activity with an IC₅₀ of 0.6 μM.</p> <p>Purity: 98.75%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p> 
<p>Kira8</p> <p style="text-align: right;">Cat. No.: HY-114368</p> <p>Bioactivity: Kira8 is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC₅₀ of 5.9 nM ^[1].</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>MKC3946</p> <p style="text-align: right;">Cat. No.: HY-19710</p> <p>Bioactivity: MKC3946 is a potent and soluble IRE1α inhibitor, used for cancer research.</p> <p>Purity: 99.77%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 

MKC8866


Cat. No.: HY-104040

Bioactivity: MKC8866 is an **IRE1 RNase** inhibitor with an **IC₅₀** of less than 0.1 μ M for IRE1 α RNase.

Purity: 98.38%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**MKC9989**

Cat. No.: HY-12399

Bioactivity: MKC9989 is a **Hydroxy aryl aldehydes (HAA)** inhibitor and also inhibits **IRE1 α** with an **IC₅₀** of 0.23 to 44 μ M.

Purity: 98.61%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg

**STF-083010**

Cat. No.: HY-15845

Bioactivity: STF-083010 is an **Ire1** inhibitor. STF-083010 inhibits Ire1 endonuclease activity, without affecting its kinase activity, after endoplasmic reticulum stress.

Purity: 98.0%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg

